ConductScience.org, home

Paper8097101

Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.

Sheldon P and 1 other. Br J Clin Pharmacol, 1993. Cited by 7 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen. Papers, record 8097101. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8097101

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen.
PubMed
Journal
Br J Clin Pharmacol
PubMed
Year
1993
PubMed
Publication types
Comparative Study, Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.4
iCite
Revised in PubMed
2019-05-12
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sheldon PP
2Pell PP

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Aminosalicylic AcidsMajor topic
Antibody FormationMajor topic
Cholera ToxinMajor topic
SulfapyridineMajor topic
SulfasalazineMajor topic
Administration, Oral
Animals
Female
Immunoglobulin A
Immunoglobulin G
Immunoglobulin M
Injections, Subcutaneous
Mice
Mice, Inbred C57BL

Source PubMed

Download CSV of topics

References14

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
172239An experiment to determine the active therapeutic moiety of sulphasalazine.Lancet1977https://conductscience.org/library/papers/72239PubMed
26121162Mode of action of sulphasalazine: an alternative view.Lancet1982https://conductscience.org/library/papers/6121162PubMed
36131674Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis.Biochem Pharmacol1983https://conductscience.org/library/papers/6131674PubMed
46407598Effect of magnesium on blood pressure.Br Med J (Clin Res Ed)1983https://conductscience.org/library/papers/6407598PubMed
56746103Gut mucosal, salivary and serum antitoxic and antibacterial antibody responses in Swedes after oral immunization with B subunit-whole cell cholera vaccine.Int Arch Allergy Appl Immunol1984https://conductscience.org/library/papers/6746103PubMed
66151882The long term effects of sulphasalazine in the treatment of rheumatoid arthritis and a comparative study with penicillamine.Clin Rheumatol1984https://conductscience.org/library/papers/6151882PubMed
71360861Effect of sulphasalazine on antibody response to oral antigen.Br J Rheumatol1992https://conductscience.org/library/papers/1360861PubMed
82872187Inhibition of cytotoxicity by sulfasalazine. II. Sulfasalazine and sulfapyridine inhibit different stages of the NK and NKCF lytic processes.Immunopharmacology1986https://conductscience.org/library/papers/2872187PubMed
93623690Role of Peyer's patch in the intestinal immune response to cholera toxin in enterically immunized rats.Infect Immun1987https://conductscience.org/library/papers/3623690PubMed
102899645Sulfasalazine treatment and lymphocyte function in patients with rheumatoid arthritis.J Rheumatol1988https://conductscience.org/library/papers/2899645PubMed
112899646In vitro immunomodulatory effects of sulfasalazine and its metabolites.J Rheumatol1988https://conductscience.org/library/papers/2899646PubMed
122902897Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action?Br J Rheumatol1988https://conductscience.org/library/papers/2902897PubMed
131968449The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells.Immunopharmacology1990https://conductscience.org/library/papers/1968449PubMed
142860942Which component of sulphasalazine is active in rheumatoid arthritis?Br Med J (Clin Res Ed)1985https://conductscience.org/library/papers/2860942PubMed

Download CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn Papers
7763101Evidence for differential effects of sulphasalazine on systemic and mucosal immunity in rheumatoid arthritis.Ann Rheum Dis1995https://conductscience.org/library/papers/7763101

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/8097101

GET https://conductscience.org/api/papers/v1/8097101/authors